BenzingaSeptember 30, 2026 at 10:04 AM NY27 Days Ago
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60
JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
